The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study - Archive ouverte HAL Access content directly
Journal Articles Joint Bone Spine Year : 2021

The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study

, , , , , , , , (1) , ,
1
Guillaume Vial
Noémie Gensous
  • Function : Author
Hélène Savel
  • Function : Author
Christophe Richez
Estibaliz Lazaro
Marie-Elise Truchetet
Fabrice Bonnet
  • Function : Author
Isabelle Pellegrin
  • Function : Author
Rodolphe Thiébaut
CHU Bordeaux [Bordeaux]
CV
Patrick Blanco
Pierre Duffau

Domains

Life Sciences [q-bio]

SANDRINE DARMIGNY  : Connect in order to contact the contributor

https://hal.inria.fr/hal-03142764

Submitted on : Tuesday, February 16, 2021-11:53:50 AM

Last modification on : Tuesday, July 5, 2022-5:38:38 PM

Not file

Dates and versions

hal-03142764 , version 1 (16-02-2021)

Identifiers

Cite

Guillaume Vial, Noémie Gensous, Hélène Savel, Christophe Richez, Estibaliz Lazaro, et al.. The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study. Joint Bone Spine, 2021, 88 (2), pp.105097. ⟨10.1016/j.jbspin.2020.105097⟩. ⟨hal-03142764⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite
12 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More